The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple ...

GSK plc (LSE/NYSE: GSK) has today released global survey data showing that over half (52%) of people aged 50-60 feel younger than their age—and nearly a fifth (19%) feel as much as a decade younger.

Americans may end up paying more for their medicines as well as facing shortages of drugs they need. So it's possible there ...

China’s response to new United States (U.S.) tariffs could complicate the supply of important medicines, an analysis of data ...

U.K. regulators cleared a multiple myeloma drug GSK withdrew from market three years ago. Elsewhere, an investment firm pressed Elevation Oncology to liquidate and the FDA relaxed risk monitoring ...

ShareIt does not take rocket science to understand the importance and imperative of the factors and features that act as catalysts to increased economic productivity. Chief amongst these are solid ...

Abu Dhabi, brings together key partners including PureHealth’s Rafed, AD Ports Group’s Khalifa Economic Zones Abu Dhabi (KEZAD), Abu ...

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in ...

The UK on Thursday authorized GSK’s Blenrep to treat certain multiple myeloma patients in two different regimens, marking the ...

The London-based pharmaceutical company said Blenrep, or belantamab mafodotin, was approved for the treatment of adult patients with multiple myeloma in combination with bortezomib plus dexamethasone, ...

GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was ...